Literature DB >> 3162683

Beneficial effect of heparin in the management of patients with APL.

C F Hoyle1, D M Swirsky, L Freedman, F G Hayhoe.   

Abstract

115 patients with acute promyelocytic leukaemia (APL) were studied retrospectively to evaluate prognostic factors and assess therapeutic approaches, particularly the use of heparin in the management of disseminated intravascular coagulation (DIC). The remission rate was 86% (30/35 patients) in those who received heparin and 49% (39/80 patients) in those who received no heparin (P = 0.0002). This difference in remission rates was accounted for by a marked decrease in the number of haemorrhagic deaths, especially those due to intracranial haemorrhage (ICH), in the heparin treated group. Other factors associated with a poor remission rate were prothrombin ratio (PTR) greater than 1.3 (P = 0.008), fibrinogen less than 1.5 g/l (P = 0.02) and WCC greater than 2.0 x 10(9)/l (P = 0.03).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162683     DOI: 10.1111/j.1365-2141.1988.tb04204.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

Review 1.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

Review 2.  Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.

Authors:  Peter H Wiernik
Journal:  Med Oncol       Date:  2014-07-22       Impact factor: 3.064

Review 3.  Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.

Authors:  Maximilian Stahl; Martin S Tallman
Journal:  Leuk Lymphoma       Date:  2019-12-16

4.  Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH.

Authors:  Tzu-Fei Wang; Robert S Makar; Darko Antic; Jerrold H Levy; James D Douketis; Jean M Connors; Marc Carrier; Jeffrey I Zwicker
Journal:  J Thromb Haemost       Date:  2020-12       Impact factor: 5.824

Review 5.  Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.

Authors:  Arturo J Martí-Carvajal; Vidhu Anand; Ivan Solà
Journal:  Cochrane Database Syst Rev       Date:  2015-06-24

Review 6.  Disseminated intravascular coagulation: diagnosis and treatment.

Authors:  T Baglin
Journal:  BMJ       Date:  1996-03-16

Review 7.  Acute promyelocytic leukaemia in the all trans retinoic acid era.

Authors:  T G DeLoughery; S H Goodnight
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

Review 8.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

9.  Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.

Authors:  T Haferlach; W Gassmann; H Löffler; C Jürgensen; J Noak; W D Ludwig; E Thiel; D Haase; C Fonatsch; R Becher
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

10.  Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse.

Authors:  T Haferlach; H Löffler; B Glass; W Gassmann
Journal:  Clin Investig       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.